Key result
Plasma metabolite panel identifies coronary atherosclerosis with high accuracy, reaching an AUC of ~0.93.
Why the study?
Does a multi-omics biomarker panel accurately diagnose the occurrence and severity of coronary atherosclerosis compared to healthy controls?
Population
443 participants, including coronary atherosclerosis patients and healthy controls, from three independent…
Comparison
Multi-omics biomarker panel (plasma metabolites) vs Healthy controls
Design
Cohort, blinded validation cohort
Authors
Loading...
A multi-omics biomarker panel based on plasma metabolites demonstrated high diagnostic accuracy for detecting the occurrence and severity of coronary atherosclerosis.
Observational (n=443)
Does a multi-omics biomarker panel accurately diagnose the occurrence and severity of coronary atherosclerosis compared to healthy controls?
Effect estimate: AUC >0.933 (95% CI 0.828-0.984)
A multi-omics biomarker panel based on plasma metabolites demonstrated high diagnostic accuracy for detecting the occurrence and severity of coronary atherosclerosis.
He et al. (2025) conducted an observational in Coronary atherosclerosis (n=443). Plasma metabolite biomarkers vs. Healthy controls was evaluated on Diagnosis of coronary atherosclerosis severity (AUC >0.933, 95% CI 0.828-0.984). A plasma metabolite biomarker panel effectively distinguished coronary atherosclerosis stages from healthy controls, achieving an AUC >0.933 (95% CI 0.828-0.984).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: